Emergent BioSolutions reported $182.8M in Selling and Administration Expenses for its fiscal quarter ending in June of 2023.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
ALKERMES USD 190.54M 6.1M Sep/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amarin USD 18.97M 1.03M Dec/2025
ANI Pharmaceuticals USD 94.86M 3.2M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Exelixis USD 154.56M 6.93M Sep/2026
Glaxosmithkline GBP 2.38B 264M Sep/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Merck USD 2.86B 25M Sep/2026
Moderna USD 282M 66M Sep/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Pacira USD 950.8M 858.99M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
United Therapeutics USD 184.1M 22.6M Sep/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024